§ 520.1860 Pradofloxacin.

(a) Specifications. Each milliliter of suspension contains 25 milligrams (mg) pradofloxacin.

(b) Sponsor. See No. 000859 in § 510.600(c) of this chapter.

(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this drug in food-producing animals.

(d) Conditions of use in cats—(1) Amount. Administer 3.4 mg/lb (7.5 mg/kg) body weight once daily for 7 consecutive days.

(2) Indications for use. For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida, Streptococcus canis, Staphylococcus aureus, Staphylococcus felis, and Staphylococcus pseudintermedius.

§ 520.1870 Praziquantel tablets.

(a) Specifications. Each tablet contains:

(1) 34 milligrams (mg) praziquantel.

(2) 11.5 or 23 mg praziquantel.

(b) Sponsors. See sponsors in § 510.600(c) of this chapter:

(1) No. 000859 for use of the product described in paragraph (a)(1) of this section, as in paragraph (c)(1) of this section; and for use of the product described in paragraph (a)(2) of this section, as in paragraph (c)(2) of this section.

(2) No. 000859 for use of the product described in paragraph (a)(1) of this section for use as in paragraph (d)(1) of this section.

(c) Special considerations. See § 500.25 of this chapter.

§ 520.1871 Praziquantel and pyrantel.

(a) Specifications. (1) Each tablet contains 13.6 milligrams (mg) praziquantel and 54.3 mg pyrantel base (as pyrantel pamoate), 18.2 mg praziquantel and 72.6 mg pyrantel base (as pyrantel pamoate), or 27.2 mg praziquantel and 108.6 mg pyrantel base (as pyrantel pamoate).

(2) Each chewable tablet contains 30 mg praziquantel and 30 mg pyrantel pamoate or 114 mg praziquantel and 114 mg pyrantel pamoate.

(b) Sponsors. See sponsors in § 510.600(c) for use as in paragraph (d) of this chapter.

(1) See No. 000859 for use of tablets described in paragraph (a)(1) of this section for use as in paragraph (d)(1) of this section.

(2) See No. 051311 for use of tablets described in paragraph (a)(2) of this section for use as in paragraph (d)(2) of this section.

(c) Special considerations. See § 500.25 of this chapter.
§ 520.1872 Praziquantel, pyrantel pamoate, and febantel tablets.

(d) Conditions of use—(1) Cats—(i) Dosage. Administer a minimum dose of 2.27 mg praziquantel and 9.2 mg pyrantel pamoate per pound of body weight according to the dosing tables on labeling. May be given directly by mouth or in a small amount of food. Do not withhold food prior to or after treatment. If reinfection occurs, treatment may be repeated.

(ii) Indications for use. For removal of tapeworms (Dipylidium caninum and Taenia taeniaeformis), hookworms (Ancylostoma caninum, A. c. tubaeforme), and large roundworms (Toxocara cati) in cats and kittens.

(iii) Limitations. Not for use in kittens less than 2 months of age or weighing less than 2.0 pounds. Consult your veterinarian before giving to sick or pregnant animals.

(ii) Dogs—(i) Amount. Administer a minimum dose of 5 mg praziquantel and 5 mg pyrantel pamoate per kilogram body weight (2.27 mg praziquantel and 2.27 mg pyrantel pamoate per pound body weight) according to the dosing tables on labeling.

(ii) Indications for use. For the treatment and control of roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum, Uncinaria stenocephala), and tapeworms (Dipylidium caninum and Taenia pisiformis) in dogs and puppies.

§ 520.1872 Praziquantel, pyrantel pamoate, and febantel tablets.

(a) Specifications. Each tablet or chewable tablet contains either:

(i) Tablet No. 1: 22.7 milligrams praziquantel, 22.7 milligrams pyrantel base, and 113.4 milligrams febantel; or

(ii) Tablet No. 2: 68 milligrams praziquantel, 68 milligrams pyrantel base, and 340.2 milligrams febantel.

(iii) Tablet No. 3: 136 milligrams (mg) praziquantel, 136 mg pyrantel base, and 680.4 mg febantel.

(b) Sponsor. See 000859 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. Administer as a single dose directly by mouth or in a small amount of food as follows:

<table>
<thead>
<tr>
<th>Kilograms</th>
<th>Pounds</th>
<th>Tablet no. 1</th>
<th>Tablet no. 2</th>
<th>Tablet no. 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.9 to 1.8</td>
<td>2 to 4</td>
<td>1/2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.3 to 3.2</td>
<td>5 to 7</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.6 to 5.4</td>
<td>8 to 12</td>
<td>1/2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>5.9 to 8.2</td>
<td>13 to 18</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.6 to 11.4</td>
<td>19 to 25</td>
<td>2.1/2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.8 to 13.6</td>
<td>26 to 30</td>
<td>1</td>
<td>1/2</td>
<td></td>
</tr>
<tr>
<td>14.1 to 20.0</td>
<td>31 to 44</td>
<td></td>
<td>2</td>
<td>1/2</td>
</tr>
<tr>
<td>20.4 to 27.2</td>
<td>45 to 60</td>
<td></td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>27.7 to 40.9</td>
<td>61 to 90</td>
<td></td>
<td>2</td>
<td>1/2</td>
</tr>
<tr>
<td>41.3 to 54.5</td>
<td>91 to 120</td>
<td></td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

(ii) Indications for use. For the removal of tapeworms (Dipylidium caninum, Taenia pisiformis, Echinococcus granulosus); hookworms (Ancylostoma caninum, Uncinaria stenocephala); ascarids (Toxocara canis, Toxascaris leonina); and whipworms (Trichuris vulpis) and for the removal and control of tapeworm Echinococcus multilocularis in dogs.

(iii) Limitations. Do not use in pregnant animals. Do not use in dogs weighing less than 0.9 kilogram (2 pounds) or puppies less than 3 weeks of age. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1880 Prednisolone tablets.

(a) Specifications. Each tablet contains 5 or 20 milligrams prednisolone.

(b) Sponsor. See No. 061690 in §510.600(c)(2) of this chapter.

(c) Special considerations. (1) Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate parturition followed by dystocia, fetal death, retained placenta, and metritis.

(2) Do not use in viral infections. Systemic therapy with prednisolone is contraindicated in animals with peptic ulcer, corneal ulcer, and Cushingoid syndrome. The presence of diabetes, osteoporosis, predisposition to thrombophlebitis, hypertension, congestive heart failure, renal insufficiency, and active tuberculosis necessitates carefully controlled use. Some of the above conditions occur only